Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eli Lilly and CoXSWX:LLY +1.61%26 Shiller PE Ratio is 113.92 as of Sep. 16, 2026, which is 104% above its 10-year median of 55.96. GuruFocus rates XSWX:LLY with a GF Score™ of 26/100 and a GF Value™ of CHF1,254.83 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 529 Drug Manufacturers companies, Eli Lilly and Co ranks worse than 93.57% on this metric.
As of today (2026-09-16), Eli Lilly and Co's current share price is CHF945.00. Eli Lilly and Co's E10 for the quarter that ended in Jun. 2026 was CHF8.30. Eli Lilly and Co's Shiller PE Ratio for today is 113.92.
The historical rank and industry rank for Eli Lilly and Co's Shiller PE Ratio or its related term are showing as below:
XSWX:LLY'
s Shiller PE Ratio Range Over the Past 10 Years
Min: 23.03 Med: 55.96 Max: 172.05
Current: 111.87
During the past years, Eli Lilly and Co's highest Shiller PE Ratio was 172.05. The lowest was 23.03. And the median was 55.96.
XSWX:LLY's Shiller PE Ratio is ranked worse than 93.57% of 529
companies
in the Drug Manufacturers industry
Industry Median: 24.61
vs XSWX:LLY: 111.87
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
Eli Lilly and Co's adjusted earnings per share data for the three months ended in Jun. 2026 was CHF6.275. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is CHF8.30 for the trailing ten years ended in Jun. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Eli Lilly and Co (XSWX:LLY) Shiller PE Ratio Explanation
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Be Aware
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Eli Lilly and Co Shiller PE Ratio Related Terms
Eli Lilly and Co Shiller PE Ratio Historical Data
* Premium members only.
The historical data trend for Eli Lilly and Co's Shiller PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:LLY vs JNJ, ABBV, MRK: Shiller PE Ratio Comparison
For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eli Lilly and Co Shiller PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Eli Lilly and Co's Shiller PE Ratio falls into.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eli Lilly and Co's E10 for the quarter that ended in Jun. 2026 is calculated as:
For example, Eli Lilly and Co's adjusted earnings per share data for the three months ended in Jun. 2026 was:
Add all the adjusted EPS together and divide 10 will get our E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Eli Lilly and Co (XSWX:LLY) has a Shiller PE Ratio of 113.92 as of Sep. 16, 2026. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Eli Lilly and Co and its competitors. This is 104% above median its historical median of 55.96. Over the past decade, Eli Lilly and Co's Shiller PE Ratio has ranged from 23.03 to 172.05. According to the industry distribution chart, Eli Lilly and Co ranks #495 out of 529 companies in the Drug Manufacturers industry, placing it in the top 93.6%.
Is Eli Lilly and Co's Shiller PE Ratio too high?
Eli Lilly and Co's current Shiller PE Ratio of 113.92 is 104% above median its 10-year median of 55.96. Over the past 10 years, this metric has ranged from a low of 23.03 to a high of 172.05. The Drug Manufacturers industry median Shiller PE Ratio is 24.61. Eli Lilly and Co's value of 113.92 is 362.9% above this industry median. Based on the distribution chart, Eli Lilly and Co ranks #495 out of 529 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Eli Lilly and Co has a GF Score™ of 26/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's Shiller PE Ratio compare to JNJ and ABBV?
According to the Drug Manufacturers industry distribution chart, Eli Lilly and Co ranks #495 out of 529 companies for Shiller PE Ratio. This places Eli Lilly and Co in the lower half of its industry. The industry median Shiller PE Ratio is 24.61. Eli Lilly and Co's value of 113.92 is 362.9% above this benchmark. Historically, Eli Lilly and Co's own Shiller PE Ratio has ranged from 23.03 to 172.05 over the past decade. While the company's 10-year median is 55.96 vs. the industry median of 24.61, Eli Lilly and Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shiller PE Ratio for a Drug Manufacturers company?
The median Shiller PE Ratio among Drug Manufacturers companies is 24.61, based on 529 companies in the industry. Companies in the top quartile (top 25%) have a Shiller PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Shiller PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eli Lilly and Co's current Shiller PE Ratio of 113.92 is 362.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shiller PE Ratio mean?
A high Shiller PE Ratio can signal that a stock is expensive relative to its fundamentals. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Eli Lilly and Co and its competitors. For the Drug Manufacturers industry, the median Shiller PE Ratio is 24.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eli Lilly and Co's current Shiller PE Ratio is 113.92, which is 104% above median its own 10-year median of 55.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (XSWX:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF1,254.83, compared to a current price of CHF945.00 — trading 24.7% below its estimated fair value. The current Shiller PE Ratio is 113.92, which is 104% above median its 10-year median of 55.96 and 362.9% above the Drug Manufacturers industry median of 24.61. Eli Lilly and Co's overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shiller PE Ratio calculated?
Shiller PE Ratio is calculated from a company's financial statements. For Eli Lilly and Co (XSWX:LLY), the current Shiller PE Ratio is 113.92 as of Sep. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eli Lilly and Co (XSWX:LLY) Overvalued in 2026?
Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued.
The current stock price of CHF945.00 is trading 24.7% below its estimated GF Value™ of CHF1,254.83.
GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.
Key valuation signals for XSWX:LLY:
Shiller PE Ratio: 113.92 (104% above median its 10-year median of 55.96)
GF Value™: CHF1,254.83 vs. price of CHF945.00 (24.7% below fair value)
Industry Position: 362.9% above the Drug Manufacturers median (#495 of 529)
No single metric tells the full story. See the XSWX:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
26GF Score
Get the complete analysis for XSWX:LLY
Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:LLY has been successfully added to your 
